10x Genomics Lifts 2026 Sales Outlook After Atera Shipments

The Tip Desk · November 8, 2026 · 3 min read

The company now expects full-year 2026 revenue of $625 million to $635 million after third-quarter sales of $150.7 million.

10x Genomics, Inc. (TXG) raised its full-year 2026 revenue outlook after beginning global commercial shipments of Atera, its spatial whole-transcriptome platform, and after a third quarter in which consumables carried the business.

The life science technology company now expects 2026 revenue of $625 million to $635 million, versus the prior range of $610 million to $630 million. Excluding non-recurring license and royalty revenue tied to patent litigation settlements in both 2026 and 2025, the company said that range represents 4% to 6% growth over full-year 2025.

Third-quarter revenue was $150.7 million, up 1% from $149.0 million a year earlier. Gross margin was 75%, compared with 67% in the year-ago quarter. The company said the increase was primarily due to lower inventory write-downs and changes in product mix.

Co-founder and Chief Executive Serge Saxonov said the biggest highlight of the quarter was the start of commercial shipments of Atera, and that enthusiasm for the platform had continued to build. He said the company was putting instruments in customers’ hands and was encouraged by results across the broader business, driven by continued strength in consumables.

Consumables were the core of the quarter. Total consumables revenue was $134.3 million, versus $127.9 million a year earlier. Spatial consumables were $41.2 million, compared with $35.4 million in the corresponding 2025 period. Single Cell consumables were $93.1 million, versus $92.5 million a year earlier.

Instruments remained a small share of the mix. Spatial instruments revenue was $3.1 million, down from $7.1 million a year earlier. Single Cell instruments revenue was $3.8 million, versus $4.9 million in the year-ago quarter. Total instruments revenue was $6.9 million. Services revenue was $9.0 million.

Operating expenses were $129.0 million, a 3% decrease from $132.5 million a year earlier. The company said the decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses. Operating loss was $16.1 million, compared with an operating loss of $32.2 million in the year-ago quarter. Net loss was $19.4 million, or $0.15 a share, versus a net loss of $27.5 million, or $0.22 a share, a year earlier.

United States revenue was $82.1 million, up from $77.2 million a year earlier. Europe, Middle East and Africa revenue was $38.8 million, versus $41.6 million in the corresponding 2025 period. Asia-Pacific revenue was $26.0 million, including $15.2 million from China.

Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026.

The company also introduced Sentira, a cloud analysis platform it said is powered by NVIDIA accelerated computing for spatial data processing and Anthropic’s Claude for agentic AI analysis of single-cell data. Saxonov said that as biology enters a new era of AI and data maximalism, 10x is positioned to benefit and to be a key enabler of progress going forward.

The second-quarter outlook had already been lifted to $610 million to $630 million, from $600 million to $625 million after the first quarter, when the company had held that original range. The third-quarter raise extends that sequence. Excluding settlement-related license and royalty revenue in both years, the new 2026 range implies 4% to 6% growth over full-year 2025, a higher band than the 2% to 5% the company had cited after the second quarter.

Atera shipments began in the third quarter after the company launched the platform in the first quarter and said it expected to start shipping in the second half of 2026. Saxonov said early demand was translating into research programs spanning discovery, translational and biopharma work. Consumables, not instruments, supplied the bulk of the $150.7 million of third-quarter sales as those instruments entered customers’ hands.